FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382051149> ?p ?o ?g. }

• W4382051149 endingPage "155641" @default.
• W4382051149 startingPage "155641" @default.
• W4382051149 abstract "Background and aims Hyperinsulinemia, hyperglucagonemia, and low-grade inflammation are frequently presented in obesity and type 2 diabetes (T2D). The pathogenic regulation between hyperinsulinemia/insulin resistance (IR) and low-grade inflammation is well documented in the development of diabetes. However, the cross-talk of hyperglucagonemia with low-grade inflammation during diabetes progression is poorly understood. In this study, we investigated the regulatory role of proinflammatory cytokine interleukin-6 (IL-6) on glucagon secretion. Methods The correlations between inflammatory cytokines and glucagon or insulin were analyzed in rhesus monkeys and humans. IL-6 signaling was blocked by IL-6 receptor-neutralizing antibody tocilizumab in obese or T2D rhesus monkeys, glucose tolerance was evaluated by intravenous glucose tolerance test (IVGTT). Glucagon and insulin secretion were measured in isolated islets from wild-type mouse, primary pancreatic α-cells and non-α-cells sorted from GluCre-ROSA26EYFP (GYY) mice, in which the enhanced yellow fluorescent protein (EYFP) was expressed under the proglucagon promoter, by fluorescence-activated cell sorting (FACS). Particularly, glucagon secretion in α-TC1 cells treated with IL-6 was measured, and RNA sequencing was used to screen the mediator underlying IL-6-induced glucagon secretion. SLC39A5 was knocking-down or overexpressed in α-TC1 cells to determine its impact in glucagon secretion and cytosolic zinc density. Dual luciferase and chromatin Immunoprecipitation were applied to analyze the signal transducer and activator of transcription 3 (STAT3) in the regulation of SLC39A5 transcription. Results Plasma IL-6 correlate positively with plasma glucagon levels, but not insulin, in rhesus monkeys and humans. Tocilizumab treatment reduced plasma glucagon, blood glucose and HbA1c in spontaneously obese or T2D rhesus monkeys. Tocilizumab treatment also decreased glucagon levels during IVGTT, and improved glucose tolerance. Moreover, IL-6 significantly increased glucagon secretion in isolated islets, primary pancreatic α-cells and α-TC1 cells. Mechanistically, we found that IL-6-activated STAT3 downregulated the zinc transporter SLC39A5, which in turn reduced cytosolic zinc concentration and ATP-sensitive potassium channel activity and augmented glucagon secretion. Conclusions This study demonstrates that IL-6 increases glucagon secretion via the downregulation of zinc transporter SLC39A5. This result revealed the molecular mechanism underlying the pathogenesis of hyperglucagonemia and a previously unidentified function of IL-6 in the pathophysiology of T2D, providing a potential new therapeutic strategy of targeting IL-6/glucagon to preventing or treating T2D." @default.
• W4382051149 created "2023-06-27" @default.
• W4382051149 creator A5014095048 @default.
• W4382051149 creator A5015676875 @default.
• W4382051149 creator A5026154106 @default.
• W4382051149 creator A5027162772 @default.
• W4382051149 creator A5031603333 @default.
• W4382051149 creator A5033673090 @default.
• W4382051149 creator A5042676208 @default.
• W4382051149 creator A5045720115 @default.
• W4382051149 creator A5052451083 @default.
• W4382051149 creator A5055641984 @default.
• W4382051149 creator A5083037234 @default.
• W4382051149 creator A5085696635 @default.
• W4382051149 creator A5089531615 @default.
• W4382051149 creator A5090039679 @default.
• W4382051149 creator A5090712009 @default.
• W4382051149 date "2023-09-01" @default.
• W4382051149 modified "2023-10-17" @default.
• W4382051149 title "Blocking IL-6 signaling improves glucose tolerance via SLC39A5-mediated suppression of glucagon secretion" @default.
• W4382051149 cites W1522924058 @default.
• W4382051149 cites W1881097431 @default.
• W4382051149 cites W1882262859 @default.
• W4382051149 cites W1971690212 @default.
• W4382051149 cites W1979306238 @default.
• W4382051149 cites W2007998678 @default.
• W4382051149 cites W2016330248 @default.
• W4382051149 cites W2018135697 @default.
• W4382051149 cites W2022930571 @default.
• W4382051149 cites W2024378513 @default.
• W4382051149 cites W2025410324 @default.
• W4382051149 cites W2032658955 @default.
• W4382051149 cites W2061391003 @default.
• W4382051149 cites W2074528335 @default.
• W4382051149 cites W2080174452 @default.
• W4382051149 cites W2084819933 @default.
• W4382051149 cites W2085073265 @default.
• W4382051149 cites W2087959519 @default.
• W4382051149 cites W2097147259 @default.
• W4382051149 cites W2113278846 @default.
• W4382051149 cites W2120682972 @default.
• W4382051149 cites W2127167047 @default.
• W4382051149 cites W2142228286 @default.
• W4382051149 cites W2142586756 @default.
• W4382051149 cites W2145697808 @default.
• W4382051149 cites W2148175667 @default.
• W4382051149 cites W2148378054 @default.
• W4382051149 cites W2150367899 @default.
• W4382051149 cites W2150702412 @default.
• W4382051149 cites W2155824086 @default.
• W4382051149 cites W2166913319 @default.
• W4382051149 cites W2169046916 @default.
• W4382051149 cites W2284282032 @default.
• W4382051149 cites W2296892613 @default.
• W4382051149 cites W2336523804 @default.
• W4382051149 cites W2518248979 @default.
• W4382051149 cites W2600127085 @default.
• W4382051149 cites W2741568582 @default.
• W4382051149 cites W2765166506 @default.
• W4382051149 cites W2794081434 @default.
• W4382051149 cites W2804103081 @default.
• W4382051149 cites W2896172858 @default.
• W4382051149 cites W2905697985 @default.
• W4382051149 cites W2911935607 @default.
• W4382051149 cites W2927163824 @default.
• W4382051149 cites W3094126390 @default.
• W4382051149 cites W3117237609 @default.
• W4382051149 cites W3118955581 @default.
• W4382051149 cites W3215596355 @default.
• W4382051149 cites W4293276053 @default.
• W4382051149 cites W4309013893 @default.
• W4382051149 cites W44929223 @default.
• W4382051149 doi "https://doi.org/10.1016/j.metabol.2023.155641" @default.
• W4382051149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37380017" @default.
• W4382051149 hasPublicationYear "2023" @default.
• W4382051149 type Work @default.
• W4382051149 citedByCount "0" @default.
• W4382051149 crossrefType "journal-article" @default.
• W4382051149 hasAuthorship W4382051149A5014095048 @default.
• W4382051149 hasAuthorship W4382051149A5015676875 @default.
• W4382051149 hasAuthorship W4382051149A5026154106 @default.
• W4382051149 hasAuthorship W4382051149A5027162772 @default.
• W4382051149 hasAuthorship W4382051149A5031603333 @default.
• W4382051149 hasAuthorship W4382051149A5033673090 @default.
• W4382051149 hasAuthorship W4382051149A5042676208 @default.
• W4382051149 hasAuthorship W4382051149A5045720115 @default.
• W4382051149 hasAuthorship W4382051149A5052451083 @default.
• W4382051149 hasAuthorship W4382051149A5055641984 @default.
• W4382051149 hasAuthorship W4382051149A5083037234 @default.
• W4382051149 hasAuthorship W4382051149A5085696635 @default.
• W4382051149 hasAuthorship W4382051149A5089531615 @default.
• W4382051149 hasAuthorship W4382051149A5090039679 @default.
• W4382051149 hasAuthorship W4382051149A5090712009 @default.
• W4382051149 hasConcept C126322002 @default.
• W4382051149 hasConcept C134018914 @default.
• W4382051149 hasConcept C164027704 @default.
• W4382051149 hasConcept C2776398474 @default.
• W4382051149 hasConcept C2776914184 @default.

• next